

1 The Effect of Productive HPV16 Infection on Global Gene Expression of Cervical
2 Epithelium

3

4 Sa Do Kang^a, Sreejata Chatterjee^a, Samina Alam^a, Anna C. Salzberg^b, Janice Milici^a,
5 Sjoerd H. van der Burg^c, Craig Meyers^{a#}

6

7 ^aDepartment of Microbiology and Immunology, Penn State College of Medicine,
8 Hershey, Pennsylvania, USA

9 ^bBioinformatics Core, Penn State College of Medicine, Hershey, Pennsylvania, USA

10 ^cDepartment of Medical Oncology, Leiden University Medical Center, Leiden, The
11 Netherlands

12

13 Running title: Cervix transcriptome during productive HPV16 infection

14

15 #Address correspondence to Craig Meyers, cmeyers@pennstatehealth.psu.edu.

16

17 Abstract word count: 245

18 Importance word count: 150

19 Text word count: 6,965

20 **Abstract**

21 Human papillomavirus (HPV) infection is the world's most common sexually
22 transmitted infection, and is responsible for most cases of cervical cancer. Previous
23 studies of global gene expression changes induced by HPV infection have focused on
24 the cancerous stages of infection, and therefore, not much is known about global gene
25 expression changes at early pre-neoplastic stages of infection. We show for the first
26 time, global gene expression changes of early stage HPV16 infection in cervical tissue
27 using 3-dimensional organotypic raft cultures that produce high levels of progeny virions.

28 cDNA microarray analysis showed that a total of 594 genes were upregulated
29 and 651 genes were downregulated at least 1.5-fold with HPV16 infection. Gene
30 ontology analysis showed that biological processes including cell cycle progression and
31 DNA metabolism were upregulated, while skin development, immune response, and cell
32 death were downregulated with HPV16 infection in cervical keratinocytes. Individual
33 genes were selected for validation at the transcriptional and translational levels
34 including UBC, which was central to the protein association network of immune
35 response genes, and top downregulated genes RPTN, SERPINB4, KRT23, and KLK8.
36 In particular, KLK8 and SERPINB4 have shown to be upregulated in cancer, which
37 contrasts our results.

38 Organotypic raft cultures that allow full progression of the HPV life-cycle have
39 allowed us to identify novel gene modulations and potential therapeutic targets of early
40 stage HPV infection in cervical tissue. Additionally, our results suggest that early stage
41 productive infection and cancerous stages of infection are distinct disease states
42 expressing different transcriptomes.

43

44 **Importance**

45 Persistent HPV infection is responsible for most cases of cervical cancer.
46 Transition from precancerous to cancerous stages of HPV infection is marked by a
47 significant reduction in virus production. Most global gene expression studies of HPV
48 infection have focused on the cancerous stages. Therefore, little is known about global
49 gene expression changes at precancerous stages. For the first time, we measured
50 global gene expression changes at precancerous stages of HPV16 infection in human
51 cervical tissue producing high levels of virus. We identified a group of genes that are
52 typically overexpressed in cancerous stages to be significantly downregulated at the
53 precancerous stage. Moreover, we identified significantly modulated genes that have
54 not yet been studied in the context of HPV infection. Studying the role of these genes in
55 HPV infection will help us understand what drives the transition from precancerous to
56 cancerous stages, and may lead to development of new therapeutic targets.

57

58 **Introduction**

59 Human papilloma virus (HPV) infection is the world's most common sexually
60 transmitted infection with approximately 291 million women worldwide infected with the
61 virus at any given point in time (1). While low-risk HPV types cause benign warts in the
62 anogenital area, persistent infection with high-risk HPV types can give rise to various
63 cancers of epithelial origin. In particular, HPV is responsible for most cases of cervical
64 cancer, which is the third most common cancer in women worldwide and the most

65 common cancer in women in developing countries (2). For this reason, the mechanism
66 of HPV infection and HPV-mediated oncogenesis has been extensively studied. Early
67 viral proteins E6 and E7 have been identified as oncoproteins that play a critical role in
68 tumorigenesis and tumor maintenance by inhibiting tumor suppressor genes *TP53* and
69 *RB1*, respectively (3–10).

70 HPV initially infects dividing cells of the basal layer of the epidermis via
71 microabrasions. Most infections are naturally resolved, but in some cases, the virus
72 establishes a persistent infection, which may subsequently progress to precancerous
73 lesions that are histologically graded as cervical intraepithelial neoplasia (CIN) I to III.
74 When left untreated, these neoplastic lesions may ultimately develop into carcinoma in
75 situ and invasive cancer. In persistently infected cervical tissue with normal or low-
76 grade dysplasia the HPV genome is maintained episomally and infectious viral particles
77 are produced. In contrast, progression to severe dysplasia and invasive cancer is
78 marked by integration of viral genome into the host genome that typically results in
79 disruption of the E2 gene, subsequent upregulation of oncogenes E6 and E7, and
80 abrogation of virion production (11, 12).

81 In the past, many studies have looked into changes in whole genome expression
82 profiles of precancerous and cancerous lesions in order to better understand the
83 progression of persistent HPV infection to cervical cancer. However, most of these
84 studies focus on neoplastic lesions and cancerous lesions (13–21) and, therefore, there
85 is a gap in knowledge of global gene expression in earlier pre-neoplastic stages of the
86 disease when HPV establishes productive infection in the host. In two recent studies,
87 human keratinocytes persistently infected with HPV16 were used to measure global

88 gene expression changes (22, 23), but they used keratinocytes derived from foreskin,
89 which may not be appropriate for modeling infection in cervical tissue since HPV may
90 have tissue-specific effects (24). Furthermore, these studies used monolayer cell
91 cultures that do not produce mature virions by disallowing the virus to progress through
92 its differentiation-dependent replication life-cycle (25, 26). In other studies,
93 overexpression tools were used to examine the effect of specific HPV oncoproteins on
94 global gene expression (27, 28). Since these studies only examine the effect of
95 individual viral proteins, they do not account for the full picture of HPV infection in the
96 natural environment.

97 In this study, we used oligonucleotide microarrays to measure global gene
98 expression changes in early passage HPV16-infected human cervical keratinocytes
99 (16HCK). Organotypic raft cultures were used in order to allow the virus to go through
100 its full life-cycle. A total of 594 and 651 genes were at least 1.5-fold upregulated and
101 downregulated, respectively. Gene ontology analysis of upregulated genes identified
102 biological processes that were significantly represented including the cell cycle process
103 and DNA metabolism. In contrast, biological processes that were significantly
104 represented with downregulated genes included epidermis development, extracellular
105 matrix disassembly, and regulation of NF- κ B signaling.

106

107

108 **Results**

109 **Microarray analysis of HPV16 infection in cervical tissue.** Global gene
110 expression changes in cervical tissue infected with HPV16 at a pre-neoplastic state
111 were measured by conducting cDNA microarray analysis (GEO accession no.
112 GSE109039) on 10-day organotypic raft tissue from early passage human cervical
113 keratinocytes (HCK) persistently infected with HPV16 (16HCK). In order to create
114 16HCK cell lines, human cervical tissue from biopsies were acquired, processed, and
115 cultured with keratinocyte-selective medium to grow primary HCKs. The HCKs were
116 then electroporated with the HPV16 genome to establish persistent infection and
117 immortalization. Since HPV replication is differentiation-dependent, monolayer cell
118 culture systems cannot produce HPV virions and provide limited insight into the effect of
119 productive infection that happens *in vivo*. Also, it is difficult to study early stages of HPV
120 infection in clinical samples because early stages of infection are largely asymptomatic
121 and patients typically present at a neoplastic or cancerous stage. Moreover, clinical
122 samples may be infected with any of the numerous types and variants of HPV making it
123 difficult to study the effect of a specific virus in a controlled environment. Therefore, we
124 used organotypic raft cultures as previously described, which allows us to observe the
125 full HPV life-cycle in 3-dimensional (3D) tissue at a precancerous stage of infection
126 when HPV particles are maximally produced. The organotypic raft tissue was harvested
127 at 10 days of culture for microarray analysis when particle production is most active,
128 and 20 days of culture when particle accumulation is at its maximum to measure the
129 viral titer showing that virus particles are produced at high levels (Table 1). By infecting
130 each cell line with the same virus and subjecting the raft cultures to the same condition,

131 we are able to minimize variables and observe the specific effect of HPV infection on
132 cervical tissue.

133 The experiment was conducted in three individually derived 16HCK cell lines in
134 duplicates and raft tissue from uninfected HCKs served as control. Out of the 34,575
135 genes that were analyzed with cDNA microarray, a total of 1,245 genes were modified
136 at least 1.5-fold ($p < 0.05$) and 533 genes were modified at least 2-fold ($p < 0.05$) with
137 HPV16 infection as compared to uninfected control (Table S1). Of those genes that
138 were significantly modulated at least 1.5-fold, 594 genes were upregulated and 651
139 genes were downregulated. Table 2 and 3 show the 50 most upregulated and
140 downregulated genes in the microarray analysis. Amongst the top 50 upregulated
141 genes are those associated with cell cycle (*CDKN2A*, *CDC7*, *NASP*, *MDC1*, *NFIX*,
142 *FOXQ1*). In contrast, the 50 most downregulated genes span from those involved in
143 differentiation (*RPTN*, *LCE1D*, *LCE3C*, *LCE1E*, *S100A7*), ECM-modulation (*KLK6*, *8*, *10*,
144 *13* and *MMP 9*, *10*), immune regulation (*LCN2*, *SPNS2*, *FAM3D*, *IL1RN*, *PSG4*, *IL1F7*)
145 to antimicrobial response (*RNASE7*, *PRSS3*, *PRSS2*). This suggests that HPV
146 infection is driving the cell cycle, and disrupting epidermal differentiation and ECM
147 homeostasis while evading the immune and antimicrobial responses by downregulating
148 them.

149 While most previous global gene expression studies have focused on neoplastic
150 and cancerous stages of HPV infection (13–21), two previous studies have modeled
151 pre-neoplastic, early stage HPV infection similar to our study (22, 23). However, most
152 of the modulated genes in the two studies did not overlap with our results. One of these
153 studies reported that 135 genes were modulated with HPV infection, but only 38 (28.1%)

154 of these were modulated in the same direction and 4 of them were modulated in the
155 opposite direction in our microarray analysis (22). In the other study, a total of 966
156 genes were reported to be modulated with HPV infection, but only 15 (1.6%) of these
157 were modulated in the same direction in our microarray analysis (23). The two major
158 differences between our study and the two previous studies is that we use cervical
159 keratinocytes instead of foreskin keratinocytes, and that we use organotypic raft
160 cultures instead of monolayer cultures that do not allow HPV to complete its life cycle.
161 Using keratinocytes derived from cervical tissue, and organotypic raft cultures that allow
162 the virus to complete its life cycle in 3D tissue enables us to capture the whole picture of
163 an early stage HPV infection in the cervix.

164 While fold-change of the 50 most upregulated genes ranged between 12.1 to 2.5,
165 that of the 50 most downregulated genes ranged between 57.5 and 6 indicating that a
166 greater degree of gene modulation occurred in the downregulated genes than the
167 upregulated genes. Similarly, when the cutoff for inclusion was increased to at least 5-
168 fold modulation, only 6 genes were upregulated in contrast to 72 genes that were
169 downregulated as shown in Fig. 1. This suggests that HPV16 is disrupting the host's
170 physiology mostly by dampening many of the normal processes that may interfere with
171 the virus's survival and replication.

172 **Gene ontology analysis.** In order to identify biological pathways that are
173 significantly affected with HPV16 infection, we conducted gene ontology (GO) analysis
174 using the online tool GOrilla (29). The GO analysis result was then summarized using
175 REVIGO to combine similar GO terms for simplified visualization (30). 144 GO terms
176 that were significantly represented in upregulated genes were summarized to 82 GO

177 terms (Table S2), and 77 GO terms that were significantly represented in
178 downregulated genes were summarized to 52 GO terms using REVIGO (Table S3).

179 Amongst the genes that were upregulated with HPV16 infection, many of the
180 represented GO terms are associated with cell cycle progression (cell cycle process,
181 cell division, cell cycle phase transition, regulation of mitotic cell cycle, and cell cycle)
182 and DNA metabolism (DNA metabolic process, DNA repair, cellular response to DNA
183 damage stimulus) as shown in Fig. 2A. This suggests that persistent infection with
184 HPV16 drives cellular proliferation in cervical tissue as expected due to the presence of
185 viral oncogenes E6/E7 and consistent with previous gene expression studies (16, 19, 27,
186 31). It is known that HPV oncoproteins E6 and E7 inhibit tumor suppressor genes *TP53*
187 and *RB1* respectively, and that this is the main mechanism through which the virus
188 promotes proliferation and tumorigenesis. “Translesion synthesis,” “neuron projection
189 regeneration,” and “retina morphogenesis in camera-type eye” were amongst the
190 upregulated DNA metabolism GO terms which have not yet been reported by previous
191 global gene expression studies of HPV16 infection. Translesion synthesis is a cellular
192 DNA damage tolerance process of recovering from stalled replication forks by allowing
193 DNA replication to bypass certain lesions (32, 33). Eight genes of the translesion
194 synthesis GO category were upregulated in our analysis including *POLE2*, *UBA7*,
195 *MAD2L2*, and *RPA2* which have not yet been reported in previous global gene
196 expression studies of HPV infection. So far, not much is known about the exact role of
197 translesion synthesis in HPV infection. One previous study speculated that HPV
198 oncoprotein E6 may have inhibitory effects on translesion synthesis (34) while another
199 study reported that p80, a cellular cofactor of HPV31 replication, may downregulate

200 translesion synthesis (32). Our study shows for the first time that translesion synthesis
201 is upregulated in a productive raft culture model of HPV16, suggesting that this process
202 may facilitate viral replication and production.

203 Within the genes that were downregulated with HPV16 infection, the GO terms
204 that were significantly represented are associated with skin development (epidermis
205 development, keratinocyte differentiation), immune response (positive regulation of
206 IKK/NF- κ B signaling, antimicrobial humoral response), and cell death (cell death,
207 positive regulation of JNK cascade) as shown in Fig. 2B. Downregulation of genes
208 associated with skin development have also been observed in previous studies of HPV-
209 positive tumors (13, 17, 35). Similarly, downregulation of genes under GO terms
210 associated with immune response and cell death have been shown in previous studies
211 of HPV-positive tumors and E6 transgenic mice (18, 22, 23, 28, 36, 37). Overall, these
212 results suggest that HPV16 perturbs normal epidermal development while having a
213 hyperproliferative and immunosuppressive effect on cervical tissue. Downregulated GO
214 terms that have not yet been reported in previous global gene profiling studies of HPV
215 infection included “positive regulation of cell migration” and “regulation of platelet-
216 derived growth factor production.” In contrast to our results, previous studies of global
217 gene expression at cancerous stages of HPV infection have shown upregulation of
218 genes involved in cell migration, which is an indicator of invasive, or metastatic cancer
219 (20, 36, 38). Specifically, one study showed that *MMP9*, a well-established metastatic
220 gene, is upregulated in cervical carcinoma cell lines and tissue samples, whereas our
221 microarray analysis shows that this gene is downregulated 17.1-fold (38). Moreover,
222 *LCN2*, which is overexpressed in various cancers and prevents degradation of *MMP9*,

223 was downregulated 9.1-fold in our microarray analysis (39–46). These opposing trends
224 in modulation of cell migration genes highlights the fact that our study investigates early
225 productive stages of HPV infection, whereas the other studies focus on the cancerous
226 stages of infection when viral production is significantly decreased. We speculate that
227 cell migration genes interfere with efficient viral replication and assembly and, therefore,
228 are suppressed during the productive stages of infection, whereas these genes are
229 upregulated to facilitate tumor development and metastasis once the infection enters
230 the cancerous stages.

231 **Upregulation of cell cycle and DNA metabolism.** While GO analysis revealed
232 biological processes that are significantly affected by persistent infection of HPV16, it
233 does not provide information on interactions amongst the genes. Therefore, we further
234 examined the interaction amongst individual proteins based on published data using the
235 online tool STRING (47, 48). STRING protein-protein interaction network analysis
236 allows us to identify signaling pathways, interactions amongst signaling pathways, and
237 central proteins that have maximum interactions with other proteins within a category. A
238 protein association network was created for each of the five aforementioned categories
239 of biological processes that were broadly represented in the GO analysis: cell cycle,
240 DNA metabolism, skin development, immune response, and cell death.

241 From the upregulated genes, a protein association network was created with
242 genes from 32 GO terms related to cell cycle (Fig. 3A, Table S4). Genes that are not
243 known to be associated with any other gene in this group were excluded from the figure
244 for simplified visualization. The protein association analysis revealed 15 genes that are
245 central to the network as highlighted in red in Fig. 3A. These genes include

246 nucleoporins (*NUP 43, 85, 107*), centromere proteins (*CENP E, F, P*), and kinetochore-
247 associated proteins (*KNTC1, SKA2*). This suggests that HPV infection drives the cell
248 cycle and increases the expression of structural proteins involved in cell cycle and cell
249 division. Amongst these genes, *NUP43, NUP85, NUP107, CENPP*, and *SKA2* have not
250 yet been reported to be associated with HPV infection by previous gene expression
251 studies.

252 Similarly, a protein association network was created with genes from 42 GO
253 terms related to DNA metabolism (Fig. 3B, Table S5). Genes in this network include
254 minichromosome maintenance complex components (*MCM 3, 6, 7*), replication factors
255 (*RFC 2, 3, 5*), and DNA polymerase subunits (*POLA1, POLE, POLE2, POLD1*).
256 Amongst these genes, *POLA1, POLE*, and *POLE2* have not yet been reported to be
257 associated with HPV infection by previous gene expression studies. Previous studies
258 have shown that overexpression of MCM genes are correlated to cervical
259 carcinogenesis and specifically, *MCM7* has been shown to interact with HPV18 E6
260 oncoprotein (49, 50). These results are consistent with upregulation of cell cycle genes
261 since cell division requires DNA replication and proteins associated with DNA
262 metabolism. Additionally, our result suggests that the upregulation of MCM genes is
263 initiated at early stages of HPV infection and sustained throughout carcinogenesis.

264 **Downregulation of skin development, immune response, and cell death.**

265 Within the downregulated gene sets, we combined genes from 7 GO terms in the
266 protein association analysis for skin development, which gave 4 small networks (Fig. 3C,
267 Table S6) including a network of late cornified envelope genes (*LCE 1D, 1E, 1F, 3C, 4A,*
268 *5A*) and a network of laminins (*LAMA3, LAMB3, LAMC2*). All eight genes in the

269 network of LCEs were included in the GO term “epithelial cell differentiation” while the
270 three laminin genes were included in the GO term “epidermis development.” The LCE
271 genes encode stratum corneum proteins of the epidermis, and are all located in the
272 same region of chromosome 1 (1q21.3) suggesting that epigenetic modifications might
273 be suppressing the expression of this region as a whole. Our study shows for the first
274 time the downregulation of a network of LCE genes in HPV infection. The two previous
275 studies that analyzed global gene expression changes in early stage HPV infection may
276 not have observed changes in LCE genes since they used monolayer cultures that do
277 not allow formation of the four layers of differentiating keratinocytes in the epidermis (22,
278 23). The three laminin genes *LAMA3*, *LAMB3*, and *LAMC2* encode the three subunits
279 that make up laminin 5, which plays an important role in wound healing, keratinocyte
280 adhesion, motility, and proliferation (51, 52).

281 Genes from 16 GO terms were included in the protein association analysis for
282 inflammation (Fig. 3D, Table S7). Ubiquitin C (*UBC*), which is downregulated 2.48-fold
283 with HPV16 infection, is at the center of this network with the most associations with
284 other genes related to inflammation. *UBC* is one of the two polyubiquitin genes that are
285 involved in various cellular processes including protein degradation, protein trafficking,
286 cell-cycle regulation, DNA repair, and apoptosis (53). Other ubiquitin-related genes that
287 were significantly downregulated in our microarray analysis includes proteins that are
288 involved in ubiquitin conjugation (*UBE2G1*, *UBE2F*, *UBR4*, *UBTD1*), whereas two of the
289 four ubiquitin-related genes that were significantly upregulated are involved in
290 deubiquitination (*USP1*, *USP13*). This suggests that a decrease in ubiquitination may
291 be important in the HPV16 life-cycle, and that the virus is trying to achieve this by

292 decreasing ubiquitination and increasing deubiquitination. In previous studies, UBR4
293 has been shown to be a cellular target of HPV16 E7 oncoprotein (54, 55), and we have
294 shown that HPV16 upregulates deubiquitinase UCHL1 in order to escape host immunity
295 (56). Since ubiquitins are involved in many cellular processes, it is hard to identify
296 which specific pathway is being affected by the decrease in ubiquitination. It is possible
297 that the virus is preventing degradation of proteins that are targeted by ubiquitin. Also,
298 since our results suggest that HPV infection drives cell cycle and downregulates cell
299 death, it is possible that the downregulation of ubiquitination is involved in these
300 processes. The network also included cytokines (*IL1A*, *IL1B*, *IL36B*), MAP kinases
301 (*MAPK13*, *MAP2K4*, *MAP3K9*), proteases (*CTSD*, *CTSC*, *KLK7*, *FURIN*), serine
302 protease inhibitors (*SERPINB1*, *SERPINE1*), and antimicrobial genes (*S100A7*,
303 *RNASE7*, *PRSS3*, *HIST1H2BC*, *HIST1H2BE*, *HIST1H2BG*, *LCN2*). Amongst these
304 genes, *MAP3K9*, *CTSD*, *CTSC*, *SERPINE1*, *HIST1H2BC*, *HIST1H2BE*, and
305 *HIST1H2BG* have not yet been reported to be associated with HPV infection by
306 previous gene expression studies. Of note, *RNASE7* is a broad-spectrum antimicrobial
307 protein that we have previously shown to be downregulated by HPV infection (57). In
308 terms of specific signaling pathways, regulation of I-kappaB kinase (IKK) and NF- κ B
309 signaling was significantly represented in the network (Fig. 3D, highlighted in red),
310 which is consistent with our previous study that showed suppression of NF- κ B activation
311 by HPV16 (58). Most of these genes were shown to interact with UBC (Fig. 3D), and it
312 is known that ubiquitination and proteolytic degradation of NF- κ B inhibitor I κ B can lead
313 to NF- κ B activation (59). This suggests that HPV16 is evading the immune system by

314 suppressing the NF- κ B pathway, and that this suppression may be mediated by
315 downregulation of UBC.

316 Lastly, genes from 4 GO terms were included in the protein association analysis
317 for cell death and gave 5 small networks (Fig. 3E, Table S8). The networks include
318 genes from the JNK signaling pathway (*TIAM1*, *IL1B*, *VANGL2*, *CTGF*, *WNT7B*)
319 suggesting that HPV16 may be suppressing cell death, and promoting transformation
320 and tumorigenesis through this pathway. This is consistent with our previous study that
321 showed downregulation of cell death with HPV infection (60). Both NF- κ B and JNK
322 pathways are downstream of TNF signaling, and TNF ligands and receptors
323 (*TNFRSF19*, *LITAF*, *TNFSF9*) were downregulated in the microarray. This suggests
324 that HPV16 is downregulating NF- κ B and JNK pathways via TNF signaling
325 downregulation. Amongst these genes, *TIAM1*, *VANGL2*, *WNT7B*, *TNFRSF19*, and
326 *LITAF* have not yet been reported to be associated with HPV infection by previous gene
327 expression studies.

328 **Gene transcription changes correlate with changes in protein expression.**

329 Of the numerous biological processes that were identified with GO analysis, we wanted
330 to focus on processes and pathways that we felt were unique and most relevant to HPV
331 infection and life-cycle. Therefore, four genes that were modulated at least 10-fold were
332 selected for validation from processes involving epidermal development and
333 differentiation (*KLK8*, *RPTN*, *KRT23*), and immune response (*SERPINB4*). Additionally,
334 *UBC* was selected for validation since it was shown to be central to the protein
335 association network of inflammation (Fig. 3D), and cyclin-dependent kinase 2 (*CDK2*)
336 was included for analysis as a marker of proliferation. In our microarray analysis *KLK8*,

337 *RPTN*, *KRT23*, *SERPINB4*, and *UBC* were downregulated 25.8, 57.5, 11.1, 48, 2.48-
338 fold, respectively, and *CDK2* was upregulated 1.74-fold with HPV16 infection. *KRT23* is
339 a structural protein in epithelial cells, whereas *KLK8* and *RPTN* are involved in skin
340 barrier proteolytic cascade and cornified cell envelope formation, respectively (61, 62).
341 Recently, studies have reported that *KRT23* may be involved in other cellular processes
342 including cell cycle regulation and apoptosis (63), which are key processes that are
343 modulated by HPV infection in our study. *KRT23* has not yet been reported by any
344 other gene expression studies of HPV infection and, therefore, could be developed into
345 a novel biomarker of productive HPV infection. In a recent gene expression profiling
346 study, *SERPINB4* was shown to be downregulated in early stage HPV infection
347 consistent with our analysis (23). *SERPINB4* is a serine protease inhibitor that is
348 overexpressed in inflammatory skin diseases and various cancers including squamous
349 cell carcinomas, and may play a critical role in the immune response against HPV
350 replication and virion production as it has been shown that increased *SERPINB4*
351 expression can activate NF- κ B (64–70). Similarly, *KLK8* has been shown to be
352 overexpressed in cervical cancer, ovarian cancer, and oral squamous cell carcinoma
353 (71–74). So far, not much is known about these proteins in the context of pre-
354 neoplastic HPV infections, and therefore, they could potentially become biomarkers or
355 therapeutic targets of HPV infection at its early stages. In particular, overexpression of
356 *SERPINB4* and *KLK8* in cancers prominently contrasts our microarray data that
357 includes the two genes amongst the top downregulated genes. This contrast highlights
358 the different microenvironments of the precancerous and cancerous states of HPV
359 infection, and understanding the role of *SERPINB4* and *KLK8* may provide critical

360 insight into the mechanism of HPV-induced carcinogenesis. For the validation
361 experiments, six new raft cultures were put up with uninfected keratinocytes isolated
362 from different cervical biopsies and six 16HCK raft cultures were put up from three
363 16HCK cell lines in duplicates. In order to validate the microarray results in new tissue
364 samples, all of the raft cultures were set up with new cell lines except for one set of
365 16HCK rafts.

366 Downregulation of *KLK8*, *RPTN*, *SERPINB4*, and upregulation of *CDK2* at the
367 transcriptional level was observed with RT-qPCR consistent with the microarray
368 analysis (Fig. 4). However, transcription of *UBC* didn't show statistically significant
369 modulation with HPV16 infection. We then further validated downregulation of *KLK8*,
370 *RPTN*, *KRT23*, and *SERPINB4* at the translational level with western blot (Fig. 5A).
371 Although *KLK8* expression was visibly downregulated with HPV16 infection in western
372 blot, statistical significance was not reached. To measure *UBC* protein expression, we
373 used an anti-ubiquitin antibody as a proxy for measuring *UBC* translation since *UBC* is
374 simply a polyubiquitin protein that accounts for the majority of basal level ubiquitin in
375 cells (53, 75). Western blot against ubiquitin showed differential ubiquitination of
376 various proteins with HPV16 infection and downregulation of monoubiquitin (Fig. 5B).
377 Lastly, downregulation of *RPTN*, *KRT23*, *SERPINB4*, and Ubiquitin were validated with
378 immunofluorescence staining (Fig. 6). In particular, *RPTN*, *KRT23*, and *SERPINB4* are
379 minimally expressed in the basal layers of both infected and uninfected controls with no
380 significant difference in expression between the two groups. In contrast, the three
381 proteins are strongly expressed in the upper layers of uninfected tissues and this

382 expression is significantly decreased with HPV16 infection. The downregulation of the
383 proteins may be attributed to the loss of the cornified layer in infected raft tissues.

384

385 **Discussion**

386 Despite widespread screening for cervical cancer and development of HPV
387 vaccines in recent decades, the burden of cervical cancer remains to be one of the
388 highest amongst female cancers worldwide. In an attempt to understand HPV infection
389 and its progression to cancer at a holistic level, many studies have investigated global
390 gene expression changes that occur with HPV infection. Most of these studies focus on
391 neoplastic lesions and cancerous lesions (13–21). This is because early stages of HPV
392 infection, which typically lasts years, is often cytologically and clinically asymptomatic
393 until it reaches neoplastic stages of infection and, therefore, the majority of clinical
394 samples are limited to these late cancerous stages of infection. As a result, there is a
395 gap in knowledge in global gene expression at pre-neoplastic stages of HPV infection.
396 In two previous studies, early passage HPV16-immortalized human keratinocytes (22)
397 and spontaneously immortalized human keratinocytes transfected with the HPV16
398 genome (23, 76) were used to measure global gene expression changes at
399 precancerous stages of HPV infection. However, these two studies used keratinocytes
400 derived from foreskin, which is not ideal for modeling HPV infection in cervical tissue
401 since the virus may have tissue-specific effects (24). Moreover, these studies used
402 monolayer cell cultures that do not allow the virus to progress through its entire life-
403 cycle. Amongst the genes that were reported to be modulated in the two studies, only
404 28.1% and 1.6% of them matched our results, and moreover, some of the genes were

405 modulated in the opposite direction (22, 23). The stark discrepancies between our
406 study and the two previous studies can be attributed to our use of organotypic raft
407 culture system instead of monolayer cell cultures. The HPV life-cycle is dependent on
408 the various stages of keratinocyte differentiation that occur in the epidermis of the skin.
409 Since the HPV life-cycle spans all layers of the epidermis (basale, spinosum,
410 granulosum, corneum), monolayer cell cultures cannot produce progeny virus particles
411 and, therefore, are limited models of HPV infection. In our study, we overcome these
412 limitations by using human cervical keratinocytes and by creating organotypic raft
413 cultures that allow the full progression of the HPV life cycle. Raft cultures were also
414 made from uninfected primary HCKs to serve as control. Viral titers were measured on
415 all 16HCK raft tissues to check for high levels of viral particle production (Table 1),
416 which confirms that the viral genome is maintained episomally allowing productive
417 infection. Integration of viral genome into the host genome, and subsequent reduction
418 in viral particle production is a hallmark event in the progression of precancerous to
419 cancerous lesions and thus, high levels of viral particle production indicates that the
420 infection is in its earlier precancerous stages. Our study presents for the first time
421 global gene expression changes in cervical tissue with productive HPV infection.

422 Our microarray data showed that the majority of the modulated genes are
423 downregulated (Fig. 1). Gene ontology analysis of the microarray data identified gene
424 categories that were significantly represented including cell cycle progression and DNA
425 metabolism in the upregulated genes, and skin development, immune response, cell
426 death in the downregulated genes (Fig. 2). The upregulation of cell cycle and DNA
427 metabolism genes, and downregulation of cell death genes reflect the proliferative

428 nature of persistent HPV16 infection and is likely the result of viral oncogenes E6 and
429 E7 inhibiting the cell cycle regulatory genes *TP53* and *RB1*, respectively.
430 Downregulation of immune response and skin development genes can be understood in
431 the context of the virus modulating the host environment to achieve efficient replication
432 and virion production. The trends of modulation in these five gene categories are
433 consistent with previously reported studies of global gene expression (13, 16–19, 22, 23,
434 27, 28, 31, 35–37).

435 Several genes were selected for validation at the transcription and translational
436 levels based on the degree of fold-change, relevance to the HPV life-cycle, and protein
437 association network analysis. *KLK8* and *RPTN* were selected for validation as they
438 were amongst the top downregulated genes and are both involved in epithelium
439 development. It is not surprising to see many genes involved in epithelium development
440 to be affected by HPV infection since the virus infects, replicates, and assembles in the
441 epithelium. In particular, HPV is not a lytic virus and is released from the epidermis via
442 desquamation. Repetin was downregulated 57.5-fold with HPV16 infection in our
443 microarray analysis and this downregulation was validated with qPCR, western blot, and
444 IF staining. Repetin is a component of the epidermal differentiation complex, and is
445 involved in the formation of the cornified cell envelope (CE) (62). The CE is an
446 insoluble matrix of covalently linked proteins formed beneath the plasma membrane of
447 differentiating keratinocytes and plays an important role in the skin's function as a
448 protective physical barrier against the external environment (77). In the context of HPV
449 infection, the CE may hinder virion release because of its function as a physical barrier.
450 Additionally, a previous study has shown that CEs of epithelial tissue infected with

451 HPV11 are thinner and more fragile compared to those of healthy tissue (78).
452 Therefore, it can be speculated that downregulation of Repetin by HPV may be a
453 strategy to weaken the CE and increase the efficiency of virion release.

454 *KLK8* was downregulated 25.8-fold in our microarray analysis, which was
455 validated with qPCR and western blot. *KLK8* was the most significantly downregulated
456 gene of the seven KLK genes that were downregulated with HPV16 infection: *KLK3*,
457 *KLK5*, *KLK6*, *KLK7*, *KLK10*, *KLK13* were downregulated 3.6, 4, 22.1, 8.6, 7.5, 21.5-fold,
458 respectively. A previous gene expression study has also identified a cluster of KLK
459 genes (*KLKs 5, 6, 7, 10, 11*) that are downregulated at early stages of HPV16 infection
460 (22). KLKs are a family of 15 serine proteases that are clustered on chromosome
461 19q13.4 and one of their main functions is cleaving corneodesmosomal adhesion
462 molecules in the cornified layer of the epidermis, which allows regulated desquamation
463 of keratinocytes (61, 79–81). It is counterintuitive that HPV16 infection downregulates
464 KLKs since the virus is released via desquamation. We speculate that the rate at which
465 normal epithelium desquamates is faster than the rate at which HPV virions mature in
466 the cornified layer, and therefore, the virus may be downregulating KLKs in order to
467 impede desquamation and allow virions to adequately mature before being released to
468 the surrounding environment. *KLK8* also plays a role in activation of the antimicrobial
469 peptide LL-37 and thus, HPV16 may be downregulating the protein in order to prevent
470 antimicrobial reaction (61, 82).

471 *SERPINB4*, also known as squamous cell carcinoma antigen 2 (SCCA2), is a
472 member of the serpin family of serine protease inhibitors and was downregulated 48-
473 fold in our microarray analysis. The downregulation in microarray analysis was

474 validated with qPCR, western blot, and IF staining. SERPINB4 along with SERPINB3
475 (squamous cell carcinoma antigen 2; SCCA1) have been shown to be overexpressed in
476 various types of cancers including cervical, esophageal, lung, breast, and liver cancers
477 (65, 67–69, 83–85). One of the mechanisms through which SERPINB4 contributes to
478 tumor maintenance is the inhibition of granzyme M-induced cell death(86). Additionally,
479 SERPINB4 overexpression is associated with inflammatory diseases including psoriasis
480 and atopic dermatitis (64, 66, 87–89). Remarkably, *KLK8* shares the same expression
481 pattern in these diseases: while our microarray analysis shows significant
482 downregulation during productive HPV16 infection, the overexpression of *KLK8* has
483 also been associated with both squamous cell carcinomas and inflammatory skin
484 diseases, such as psoriasis and atopic dermatitis (71–74, 90). We speculate that the
485 virus downregulates *SERPINB4* and *KLK8* during productive infection as part of a broad
486 effort to dampen the inflammatory response. Of particular note is that the two genes
487 are overexpressed in various cancers while in our study they are amongst the top
488 downregulated genes during productive HPV infection. Additionally, we have identified
489 nine other genes that are significantly downregulated in our microarray analysis, but
490 have shown to be overexpressed or contribute to disease progression in various types
491 of cancers (Table 4). This highlights the fact that early productive stages of HPV
492 infection present a vastly different microenvironment and disease state from the
493 cancerous stages of infection when virion production is significantly decreased. This
494 suggests that *KLK8* and *SERPINB4* may interfere with the HPV life-cycle or contribute
495 to the immune surveillance against the virus, and therefore, are downregulated during
496 productive infection. In contrast, the two proteins may be necessary for tumor

497 maintenance, and therefore, overexpressed during the cancerous stages of infection.
498 However, since we did not measure levels of expression of these proteins at cancerous
499 stages we cannot definitively compare the protein levels between precancerous and
500 cancerous stages. A direct comparison would require creating organotypic raft cultures
501 with cervical cancer cell lines and measuring *SERPINB4* and *KLK8* protein levels. In
502 future studies, we aim to investigate the mechanism of *KLK8* and *SERPINB4*
503 downregulation, and how the two genes affect HPV entry, intracellular trafficking,
504 replication, and assembly.

505 *UBC* was the central protein in the network of inflammatory genes that were
506 significantly downregulated with persistent HPV16 infection (Fig. 3D). Although qPCR
507 did not show a statistically significant modulation of *UBC* expression, western blot of
508 ubiquitin showed downregulation of monoubiquitin and differential pattern of protein
509 ubiquitination while IF staining showed downregulation of the protein with persistent
510 infection (Fig. 5, Fig. 6). Since ubiquitin is involved in numerous biological processes it
511 is hard to conclude which specific pathways are affected with HPV16 infection.
512 However, many proteins that are associated with *UBC* in the protein association
513 network (Fig. 3D) are a part of the NF κ B pathway, and we speculate that *UBC* plays a
514 central role in downregulating this pathway especially since it has been shown that
515 ubiquitin-proteasome pathway plays a role in NF- κ B activation. In future studies, we
516 would like to investigate the role of *UBC* in relation to top downregulated genes
517 associated with inflammation, such as *SERPINB4* and *KLK8*.

518 In conclusion, our study shows for the first time global gene expression changes
519 with productive HPV16 infection in an organotypic raft culture model. With gene

520 ontology analysis, broad gene categories were identified that were significantly
521 modulated with persistent HPV16 infection, and these results were largely consistent
522 with what previous studies have reported. In particular, we identified top downregulated
523 genes that have not yet been extensively studied in the context of HPV infection, and
524 that have potential to be developed as therapeutic targets or biomarkers. Moreover,
525 expression patterns of *SERPINB4* and *KLK8* highlighted that precancerous and
526 cancerous stages of HPV infection are two distinct disease states. Although some of
527 the observed gene modulations were consistent with what was expected from results of
528 previous studies, we also observed novel changes that have not been reported before.
529 We attribute these new findings to our unique model of organotypic raft cultures at early
530 stage HPV16 infection, which allows the virus to go through its complete life-cycle.
531 Future studies investigating how the regulation of *SERPINB4* and *KLK8* changes
532 throughout the different stages of infection may shed light on unidentified mechanisms
533 of HPV persistence and tumorigenesis.

534

535 **Materials and Methods**

536 **Creating cervical cell lines and organotypic raft cultures.** Primary human
537 cervical keratinocytes (HCK) were isolated from cervical biopsies as previously
538 described (91). The Human Subjects Protection Office of the Institutional Review Board
539 at Penn State University College of Medicine screened our study design for exempt
540 status according to the policies of this institution and the provisions of applicable federal
541 regulations and, as submitted, found not to require formal IRB review because no
542 human participants are involved as defined by the federal regulations.

543 HCK cell lines persistently infected with HPV16 (16HCK) were produced by
544 electroporating primary HCK with HPV16 plasmid DNA as previously described (92, 93).
545 The electroporated cells were cultured with mitomycin-C-treated (Enzo Life Sciences)
546 J2 3T3 feeder cells as previously described (91).
547 Organotypic raft cultures were grown as previously described (93, 94) at first or second
548 passage for primary HCK and sixth to ninth passage for 16HCK. The raft tissues were
549 harvested after 10 days for microarray analysis and 20 days for qPCR, Western blot,
550 and immunofluorescence staining. Viral gene expression has been shown to peak
551 between 10 and 12 days (95) while virion maturity reaches maximum stability around 20
552 days (96).

553 **Microarray analysis.** Raft tissue from primary HCK and 16HCK were harvested
554 at 10 days and RNA was extracted using the RNeasy Fibrous Tissue Midi Kit (Qiagen).
555 The experiment was conducted with three primary HCK and three 16HCK samples in
556 duplicates. Microarray analysis was performed using the Illumina HumanHT-12 v4
557 Expression Beadchip (Illumina, San Diego, CA), which targets over 31,000 annotated
558 genes with more than 47,000 probes derived from the National Center for Biotechnology
559 Information (NCBI) RefSeq Release 38 (November 7, 2009) and other sources. RNA
560 quality and concentration were assessed using an Agilent 2100 Bioanalyzer with RNA
561 Nano LabChip (Agilent, Santa Clara, CA). cRNA was synthesized by TotalPrep
562 Amplification (Ambion, Austin, TX) from 500 ng of RNA according to manufacturer's
563 instructions. T7 oligo (dT) primed reverse transcription was used to produce first strand
564 cDNA. cDNA then underwent second strand synthesis and RNA degradation by DNA
565 Polymerase and RNase H, followed by filtration clean up. In vitro transcription (IVT)

566 was employed to generate multiple copies of biotinylated cRNA. The labeled cRNA was
567 purified using filtration, quantified by NanoDrop, and volume-adjusted for a total of 750
568 ng/sample. Samples were fragmented, and denatured before hybridization for 18
569 hours at 58°C. Following hybridization, the beadchips were washed and fluorescently
570 labeled. Beadchips were scanned with a BeadArray Reader (Illumina, San Diego, CA).

571 The CLC Genomics Workbench 4.8 package
572 (<https://www.qiagenbioinformatics.com/>) was used to determine the significantly
573 differentially expressed genes of the HPV16+ versus primary tissue. For each
574 comparison, quantile normalization was performed followed by pairwise homogeneous
575 t-test resulting in normalized fold changes and p-values. Significantly differentially
576 expressed genes were considered to be those with $p < 0.05$ and absolute fold change
577 ≥ 1.5 .

578 **Gene ontology analysis and protein association network.** In order to
579 categorize the significant gene expression changes into gene ontology (GO) groups the
580 GOrilla package was used (<http://cbl-gorilla.cs.technion.ac.il/>) (29). Two unranked lists
581 of genes, target (significantly modulated genes) and background (all genes in the
582 microarray), were used to identify significantly enriched GO terms. We focused on the
583 sub-ontology Biological Processes for our analysis. REVIGO was used to further
584 summarize the redundancy in the GO analysis (<http://revigo.irb.hr/>) (30). In our analysis,
585 we used the similarity coefficient of 0.7 (medium size list) to summarize the GO list.

586 In order to identify protein-protein associations amongst the upregulated and
587 downregulated genes, the online tool STRING (<https://string-db.org/>) was used (48).
588 Genes from similar GO categories were pooled together to form protein association

589 networks of “cell cycle” and “DNA metabolism” for the upregulated genes, and “skin
590 development,” “immune response,” and “cell death” for the downregulated genes.

591 **Viral Titers (DNA encapsidation assay).** Viral titers of each raft experiment
592 were measured with the qPCR-based DNA encapsidation assay as previously
593 described (96, 97).

594 **RT-qPCR.** RT-qPCR was used in order to measure levels of transcription of
595 SERPINB4, KLK8, RPTN, CDK2, and UBC. The experiment was conducted with three
596 primary HCK and three 16HCK samples in duplicates. For *SERPINB4*, forward primer
597 5'-ATTCCTGATGGGACTATTGGCAATG-3', reverse primer 5'-
598 CAGCAGCACAATCATGCTTAGA-3', and probe 5'-/56-
599 FAM/ACGACACTG/ZEN/GTTCTTGTGAACGCA/3IABkFQ/-3' was used. For *KLK8*,
600 forward primer 5'-TGGGTCCGAATCAGTAGGT-3', reverse primer 5'-
601 GCAGGAACATCCACGTCTT-3', and probe 5'-/56-
602 FAM/CCCTGGATT/ZEN/CTGGAAGACCTCACC/3IABkFQ/-3' was used. For *RPTN*,
603 forward primer 5'-CCACAAATATGCCAAAGGGAATG-3', reverse primer 5'-
604 GTCATTTGGTCTCTGGAGGATG-3', and probe 5'-/56-
605 FAM/ACTGCTCTT/ZEN/GGCTGAGTTTGGAGA/3IABkFQ/-3' was used. For *CDK2*,
606 forward primer 5'-GCCTGATTACAAGCCAAGTTTC-3', reverse primer 5'-
607 CGCTTGTTAGGGTCGTAGTG-3', and probe 5'-/56-
608 FAM/AGATGGACG/ZEN/GAGCTTGTTATCGCA/3IABkFQ/-3' was used. For *UBC*,
609 forward primer 5'-GGATTTGGGTCGCAGTTCTT-3', reverse primer 5'-
610 TGGATCTTTGCCTTGACATTCT-3', and probe 5'-/56-
611 FAM/AGGTTGAGC/ZEN/CCAGTGACACCATC/3IABkFQ/-3' was used. TATA-binding

612 protein (TBP) was used as control for which forward primer 5'-
613 CACGGCACTGATTTTCAGTTCT-3', reverse primer 5'-TTCTTGC
614 TGCCAGTCTGGACT-3', and probe 5'-HEX-TGTGCACAGGAGCCAAGAGTGAAGA-
615 BHQ-1-3' was used. All primers and probes were synthesized by Integrated DNA
616 Technologies, and QuantiTect Probe RT-PCR Kit (Qiagen) was used for the PCR
617 reactions. All RT-PCR reactions were performed using the C1000 Thermal Cycler (Bio-
618 Rad). The thermal cycler was programmed for 30 minutes at 50 °C, then 15 minutes at
619 95 °C, then 42 cycles of 15 seconds at 94 °C and 1 minute at 54.5 °C.

620 **Western blot.** Raft tissue were harvested at 20 days and used to prepare total
621 protein extracts as previously described (98). The experiment was conducted with three
622 primary HCK and three 16HCK samples in duplicates. Total protein concentrations
623 were measured using the Peterson protein assay as previously described (99). The
624 total protein extracts were applied to sodium dodecyl sulfate polyacrylamide gel (8-10%)
625 and transferred to nitrocellulose membrane, then incubated overnight at 4 °C with
626 antibodies against SERPINB4 (Lifespan Biosciences, LS-C172681, 1:2000 dilution),
627 KLK8 (Abnova, H00011202-M01, 1:2000 dilution), RPTN (Lifespan Biosciences, LS-
628 B17, 1:2000 dilution), KRT23 (Abcam, ab117590, 1:2000 dilution), and ubiquitin (Cell
629 Signaling, 3933S, 1:2000 dilution). GAPDH antibody (Santa Cruz, sc-47724, 1:1000
630 dilution) was used as control. The membranes were then washed and incubated with
631 horseradish peroxidase-linked secondary antibody (GE Healthcare,
632 NA931VS/NA934VS) and developed using Amersham ECL Prime Western Blotting
633 Detection Reagent (GE Healthcare). Densitometry analysis was conducted by
634 normalizing the protein expression levels to GAPDH.

635 **Immunohistochemistry and Immunofluorescence Staining.** Raft cultures
636 were grown for 20 days and fixed in 10% buffered formalin, embedded in paraffin, and
637 4- μ m cross-sections were prepared. A section from each sample was stained with
638 hematoxylin and eosin as previously described (26).

639 For Immunofluorescence staining, the slides were submerged in xylenes for
640 deparaffinization, and then were rehydrated. Antigen retrieval was achieved by
641 submerging the slides in Tris-EDTA buffer (pH 9) in a 90 °C water bath for 10 minutes.
642 The slides were then rinsed with TBS-Tween and blocked with Background Sniper
643 (Biocare Medical). The slides were then stained with the primary antibody overnight at
644 4 °C. Each sample was stained with antibodies against SERPINB4 (Lifespan
645 Biosciences, LS-C172681, 1:2000 dilution), RPTN (Lifespan Biosciences, LS-B17,
646 1:1000 dilution), KRT23 (Abcam, ab117590, 1:500 dilution), and Ub (Cell Signaling,
647 3933S, 1:750 dilution). The slides were then rinsed with TBS-Tween 3 times and
648 stained with secondary antibody (Life Technologies, Alexa Fluor 488) diluted 1:200 for 1
649 hour at room temperature. Next, the slides were stained with Hoechst nuclear stain
650 (1:5000 dilution) for 15 minutes and rinsed with TBS-Tween twice. All antibodies were
651 diluted in Da Vinci Green diluent (Biocare Medical). The experiment was conducted
652 with three primary HCK and three 16HCK samples in duplicates. A Nikon Eclipse 80i
653 microscope and NIS Elements version 4.4 software was used to acquire images.

654 **Statistical analysis.** In order to establish statistical significance in qPCR data
655 and Western blot densitometry analysis, t-test was used with a p-value cutoff of $p < 0.05$.

656 **Accession number.** The GEO accession number for our microarray data is
657 GSE109039.

658

659 **Acknowledgments**

660 We would like to thank Lynn Budgeon for doing the raft tissue embedding, slicing of
661 sections, and staining.

662

663 **Funding**

664 Work in CM's group was supported by the National Institutes of Health grants
665 R01CA225268, R01DE018305-03S1 (NIDCR-ARRA Supplement).

666

667

668 **References**

- 669 1. Sanjosé S, Díaz M, Castellsagué X, Clifford G, Bruni L. 2007. Worldwide
670 prevalence and genotype distribution of cervical HPV in women with normal
671 cytology. *Lancet Infect Dis* 7:453–459.
- 672 2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of
673 worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 127:2893–
674 2917.
- 675 3. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6
676 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the
677 degradation of p53. *Cell* 63:1129–36.

- 678 4. Werness BA, Levine AJ, Howley PM. 1990. Association of human papillomavirus
679 types 16 and 18 E6 proteins with p53. *Science* 248:76–9.
- 680 5. Dyson N, Howley PM, Münger K, Harlow E. 1989. The human papilloma virus-16
681 E7 oncoprotein is able to bind to the retinoblastoma gene product. *Science*
682 243:934–7.
- 683 6. Boyer SN, Wazer DE, Band V. 1996. E7 protein of human papilloma virus-16
684 induces degradation of retinoblastoma protein through the ubiquitin-proteasome
685 pathway. *Cancer Res* 56:4620–4.
- 686 7. Gonzalez SL, Strelau M, He X, Basile JR, Münger K. 2001. Degradation of the
687 retinoblastoma tumor suppressor by the human papillomavirus type 16 E7
688 oncoprotein is important for functional inactivation and is separable from
689 proteasomal degradation of E7. *J Virol* 75:7583–91.
- 690 8. Gu W, Putral L, Hengst K, Minto K, Saunders NA, Leggatt G, McMillan NAJ. 2006.
691 Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector
692 delivered short hairpin RNA targeting human papillomavirus E6 and E7
693 oncogenes. *Cancer Gene Ther* 13:1023–32.
- 694 9. Hall AHS, Alexander KA. 2003. RNA interference of human papillomavirus type
695 18 E6 and E7 induces senescence in HeLa cells. *J Virol* 77:6066–9.
- 696 10. Lea JS, Sunaga N, Sato M, Kalahasti G, Miller DS, Minna JD, Muller CY. 2007.
697 Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth
698 Inhibition of Cervical Cancer Cells. *Reprod Sci* 14:20–28.

- 699 11. Cripe TP, Haugen TH, Turk JP, Tabatabai F, Schmid PG, Dürst M, Gissmann L,
700 Roman A, Turek LP, Turek LP. 1987. Transcriptional regulation of the human
701 papillomavirus-16 E6-E7 promoter by a keratinocyte-dependent enhancer, and by
702 viral E2 trans-activator and repressor gene products: implications for cervical
703 carcinogenesis. *EMBO J* 6:3745–53.
- 704 12. Sang B-C, Barbosa MS. 1992. Increased E6/E7 transcription in HPV 18-
705 immortalized human keratinocytes results from inactivation of E2 and additional
706 cellular events. *Virology* 189:448–455.
- 707 13. Wong YF, Cheung TH, Tsao GS, Lo KW, Yim SF, Wang VW, Heung MM, Chan
708 SC, Chan LK, Ho TW, Wong KW, Li C, Guo Y, Chung TK, Smith DI. 2006.
709 Genome-wide gene expression profiling of cervical cancer in Hong Kong women
710 by oligonucleotide microarray. *Int J Cancer* 118:2461–2469.
- 711 14. Sopov I, Sorensen T, Magbagbeolu M, Jansen L, Beer K, Kuhne-Heid R,
712 Kirchmayr R, Schneider A, Dürst M. 2004. Detection of cancer-related gene
713 expression profiles in severe cervical neoplasia. *Int J Cancer* 112:33–43.
- 714 15. Gius D, Funk MC, Chuang EY, Feng S, Huettner PC, Nguyen L, Bradbury CM,
715 Mishra M, Gao S, Buttin BM, Cohn DE, Powell MA, Horowitz NS, Whitcomb BP,
716 Rader J. 2007. Profiling microdissected epithelium and stroma to model genomic
717 signatures for cervical carcinogenesis accommodating for covariates. *Cancer Res*
718 67:7113–7123.
- 719 16. Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M, de Crémoux P, de La
720 Rochefordière A, Salmon R, Dorval T, Thiery JP, Couturier J, Radvanyi F,

- 721 Domany E, Sastre-Garau X. 2005. Identification of a proliferation gene cluster
722 associated with HPV E6/E7 expression level and viral DNA load in invasive
723 cervical carcinoma. *Oncogene* 24:7094–7104.
- 724 17. Pyeon D, Newton MA, Lambert PF, Den Boon JA, Sengupta S, Marsit CJ,
725 Woodworth CD, Connor JP, Haugen TH, Smith EM, Kelsey KT, Turek LP,
726 Ahlquist P. 2007. Fundamental differences in cell cycle deregulation in human
727 papillomavirus-positive and human papillomavirus-negative head/neck and
728 cervical cancers. *Cancer Res* 67:4605–4619.
- 729 18. Narayan G, Bourdon V, Chaganti S, Arias-Pulido H, Nandula S V, Rao PH,
730 Gissmann L, Dürst M, Schneider A, Pothuri B, Mansukhani M, Basso K, Chaganti
731 RSK, Murty V V. 2007. Gene dosage alterations revealed by cDNA microarray
732 analysis in cervical cancer: identification of candidate amplified and
733 overexpressed genes. *Genes Chromosomes Cancer* 46:373–84.
- 734 19. Chen Y, Miller C, Mosher R, Zhao X, Deeds J, Morrissey M, Bryant B, Yang D,
735 Meyer R, Cronin F, Gostout BS, Smith-mccune K, Schlegel R. 2003. Identification
736 of cervical cancer markers by cDNA and tissue microarrays. *CANCER Res*
737 63:1927–1935.
- 738 20. Zhai Y, Kuick R, Nan B, Ota I, Weiss SJ, Trimble CL, Fearon ER, Cho KR. 2007.
739 Gene expression analysis of preinvasive and invasive cervical squamous cell
740 carcinomas identifies HOXC10 as a key mediator of invasion. *Cancer Res*
741 67:10163–10172.
- 742 21. Fu Wong Y, Selvanayagam ZE, Wei N, Porter J, Vittal R, Hu R, Lin Y, Liao J,

- 743 Weichung Shih J, Hong Cheung T, Wing Kit Lo K, Fan Yim S, Kai Yip S, Tse
744 Ngong D, Siu N, Kit Ying Chan L, Sing Chan C, Kong T, Kutlina E, McKinnon RD,
745 Denhardt DT, Chin K-V, Kwok Hung Chung T. 2003. Expression genomics of
746 cervical cancer: molecular classification and prediction of radiotherapy response
747 by DNA microarray. *Clin Cancer Res* 9:5486–92.
- 748 22. Wan F, Miao X, Quraishi I, Kennedy V, Creek KE, Pirisi L. 2008. Gene expression
749 changes during HPV-mediated carcinogenesis: A comparison between an in vitro
750 cell model and cervical cancer. *Int J Cancer* 123:32–40.
- 751 23. Klymenko T, Gu Q, Herbert I, Stevenson A, Iliev V, Watkins G, Pollock C, Bhatia
752 R, Cuschieri K, Herzyk P, Gatherer D, Graham SV. 2017. RNASeq analysis of
753 differentiated keratinocytes reveals a massive response to late events during
754 human papillomavirus type 16 infection, including loss of epithelial barrier function.
755 *J Virol* JVI.01001-17.
- 756 24. Arany I, Evans T, Tyring SK. 1998. Tissue specific HPV expression and
757 downregulation of local immune responses in condylomas from HIV seropositive
758 individuals. *Sex Transm Infect* 74:349–53.
- 759 25. Bedell MA, Hudson JB, Golub TR, Turyk ME, Hosken M, Wilbanks GD, Laimins
760 LA. 1991. Amplification of human papillomavirus genomes in vitro is dependent
761 on epithelial differentiation. *J Virol* 65:2254–60.
- 762 26. Meyers C, Frattini MG, Hudson JB, Laimins L a. 1992. Biosynthesis of human
763 papillomavirus from a continuous cell line upon epithelial differentiation. *Science*
764 257:971–973.

- 765 27. Garner-Hamrick PA, Fostel JM, Chien W-M, Banerjee NS, Chow LT, Broker TR,
766 Fisher C. 2004. Global effects of human papillomavirus type 18 E6/E7 in an
767 organotypic keratinocyte culture system. *J Virol* 78:9041–50.
- 768 28. Duffy CL, Phillips SL, Klingelutz AJ. Microarray analysis identifies differentiation-
769 associated genes regulated by human papillomavirus type 16 E6.
- 770 29. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. 2009. GOrilla: a tool for
771 discovery and visualization of enriched GO terms in ranked gene lists. *BMC*
772 *Bioinformatics* 10:48.
- 773 30. Supek F, Bošnjak M, Škunca N, Šmuc T. 2011. Revigo summarizes and
774 visualizes long lists of gene ontology terms. *PLoS One* 6.
- 775 31. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. 2001.
776 Papillomavirus type 16 oncogenes downregulate expression of interferon-
777 responsive genes and upregulate proliferation-associated and NF-kB-responsive
778 genes in cervical keratinocytes. *J Virol* 75:4283–4296.
- 779 32. Lehoux M, Fradet-Turcotte A, Lussier-Price M, Omichinski JG, Archambault J.
780 Inhibition of human papillomavirus DNA replication by an E1-derived p80/UAF1-
781 binding peptide.
- 782 33. Huang TT, Nijman SMB, Mirchandani KD, Galardy PJ, Cohn MA, Haas W, Gygi
783 SP, Ploegh HL, Bernards R, D’Andrea AD. 2006. Regulation of monoubiquitinated
784 PCNA by DUB autocleavage. *Nat Cell Biol* 8:341–347.
- 785 34. Day T, Vaziri C. 2009. HPV E6 oncoprotein prevents recovery of stalled

- 786 replication forks independently of p53 degradation. *Cell Cycle*.
- 787 35. Buitrago-Pérez A, Garaulet G, Vázquez-Carballo A, Paramio JM, García-
788 Escudero R. 2009. Molecular signature of HPV-induced carcinogenesis: pRb, p53
789 and gene expression profiling. *Curr Genomics* 10:26–34.
- 790 36. Gius D, Funk MC, Chuang EY, Feng S, Huettner PC, Nguyen L, Bradbury CM,
791 Mishra M, Gao S, Buttin BM, Cohn DE, Powell MA, Horowitz NS, Whitcomb BP,
792 Rader J. 2007. Profiling microdissected epithelium and stroma to model genomic
793 signatures for cervical carcinogenesis accommodating for covariates. *Cancer Res*
794 67:7113–7123.
- 795 37. Mendoza-Villanueva D, Diaz-Chavez J, Uribe-Figueroa L, Rangel-Escareño C,
796 Hidalgo-Miranda A, March-Mifsut S, Jimenez-Sanchez G, Lambert P, Gariglio P.
797 2008. Gene expression profile of cervical and skin tissues from human
798 papillomavirus type 16 E6 transgenic mice. *BMC Cancer* 8.
- 799 38. Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K, Duenas A, Taja L, Mendoza P,
800 Garcia JA, Salcedo M. 2005. Overexpression of cathepsin f, matrix
801 metalloproteinases 11 and 12 in cervical cancer. *BMC Cancer* 5.
- 802 39. Yan L, Borregaard N, Kjeldsen L, Moses MA. 2001. The high molecular weight
803 urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase
804 B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of
805 MMP-9 activity by NGAL. *J Biol Chem* 276:37258–65.
- 806 40. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK,
807 Zurakowski D, Moses MA. 2009. Lipocalin 2 promotes breast cancer progression.

- 808 Proc Natl Acad Sci U S A 106:3913–8.
- 809 41. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. 2008.
810 Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis
811 in human primary breast cancer. *Breast Cancer Res Treat* 108:389–397.
- 812 42. Zhang H, Xu L, Xiao D, Xie J, Zeng H, Wang Z, Zhang X, Niu Y, Shen Z, Shen J,
813 Wu X, Li E. 2007. Upregulation of neutrophil gelatinase-associated lipocalin in
814 oesophageal squamous cell carcinoma: significant correlation with cell
815 differentiation and tumour invasion. *J Clin Pathol* 60:555–61.
- 816 43. Friedl A, Stoesz SP, Buckley P, Gould MN. 1999. Neutrophil gelatinase-
817 associated lipocalin in normal and neoplastic human tissues. Cell type-specific
818 pattern of expression. *Histochem J* 31:433–441.
- 819 44. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden
820 M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli
821 S. 2004. Gene expression profiles in primary ovarian serous papillary tumors and
822 normal ovarian epithelium: Identification of candidate molecular markers for
823 ovarian cancer diagnosis and therapy. *Int J Cancer* 112:14–25.
- 824 45. Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I, Hamilton SR, Zhang W.
825 2009. NGAL decreases E-cadherin-mediated cell–cell adhesion and increases
826 cell motility and invasion through Rac1 in colon carcinoma cells. *Lab Investig*
827 89:531–548.
- 828 46. Iannetti A, Pacifico F, Acquaviva R, Lavorgna A, Crescenzi E, Vascotto C, Tell G,
829 Salzano AM, Scaloni A, Vuttariello E, Chiappetta G, Formisano S, Leonardi A.

- 830 2008. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-
831 regulated gene, is a survival factor for thyroid neoplastic cells. *Proc Natl Acad Sci*
832 *U S A* 105:14058–63.
- 833 47. Franceschini A, Lin J, Von Mering C, Jensen LJ. 2016. SVD-phy: Improved
834 prediction of protein functional associations through singular value decomposition
835 of phylogenetic profiles. *Bioinformatics* 32:1085–1087.
- 836 48. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J,
837 Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, Von
838 Mering C. 2015. STRING v10: Protein-protein interaction networks, integrated
839 over the tree of life. *Nucleic Acids Res* 43:D447–D452.
- 840 49. Kühne C, Banks L. 1998. E3-ubiquitin ligase/E6-AP links multicopy maintenance
841 protein 7 to the ubiquitination pathway by a novel motif, the L2G box. *J Biol Chem*
842 273:34302–34309.
- 843 50. Das M, Prasad SB, Yadav SS, Govardhan HB, Pandey LK, Singh S, Pradhan S,
844 Narayan G. 2013. Over expression of minichromosome maintenance genes is
845 clinically correlated to cervical carcinogenesis. *PLoS One* 8.
- 846 51. Schneider H, Mule C, Pacho F. 2007. Biological function of laminin-5 and
847 pathogenic impact of its deficiency. *Eur J Cell Biol* 86:701–717.
- 848 52. Amano S, Akutsu N, Ogura Y, Nishiyama T. 2004. Increase of laminin 5 synthesis
849 in human keratinocytes by acute wound fluid, inflammatory cytokines and growth
850 factors, and lysophospholipids. *Br J Dermatol* 151:961–970.

- 851 53. Radici L, Bianchi M, Crinelli R, Magnani M. 2013. Ubiquitin C gene: Structure,
852 function, and transcriptional regulation. *Adv Biosci Biotechnol* 4:1057–1062.
- 853 54. Huh K-W, Demasi J, Ogawa H, Nakatani Y, Howley PM, Mü K. 2005. Association
854 of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa
855 retinoblastoma protein-associated factor, p600.
- 856 55. White EA, Sowa ME, Tan MJA, Jeudy S, Hayes SD, Santha S, Münger K, Harper
857 JW, Howley PM. 2012. Systematic identification of interactions between host cell
858 proteins and E7 oncoproteins from diverse human papillomaviruses. *Proc Natl
859 Acad Sci U S A* 109:E260-7.
- 860 56. Karim R, Tummers B, Meyers C, Biryukov JL, Alam S, Backendorf C, Jha V,
861 Offringa R, van Ommen GJB, Melief CJM, Guardavaccaro D, Boer JM, van der
862 Burg SH. 2013. Human papillomavirus (HPV) upregulates the cellular
863 deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response.
864 *PLoS Pathog* 9.
- 865 57. Karim R, Meyers C, Backendorf C, Ludigs K, Offringa R, van Ommen GJB, Melief
866 CJM, van der Burg SH, Boer JM. 2011. Human papillomavirus deregulates the
867 response of a cellular network comprising of chemotactic and proinflammatory
868 genes. *PLoS One* 6.
- 869 58. Tummers B, Goedemans R, Pelascini LPL, Jordanova ES, van Esch EMG,
870 Meyers C, Melief CJM, Boer JM, van der Burg SH. 2015. The interferon-related
871 developmental regulator 1 is used by human papillomavirus to suppress NFκB
872 activation. *Nat Commun* 6:6537.

- 873 59. Magnani M, Crinelli R, Bianchi M, Antonelli a. 2000. The ubiquitin-dependent
874 proteolytic system and other potential targets for the modulation of nuclear factor-
875 kB (NF-kB). *Curr Drug Targets* 1:387–99.
- 876 60. Ma W, Tummers B, van Esch EMG, Goedemans R, Melief CJM, Meyers C, Boer
877 JM, van der Burg SH. 2016. Human papillomavirus downregulates the expression
878 of IFITM1 and RIPK3 to escape from IFN γ - and TNF α -mediated antiproliferative
879 effects and necroptosis. *Front Immunol* 7:496.
- 880 61. Eissa A, Amodeo V, Smith CR, Diamandis EP. 2011. Kallikrein-related peptidase-
881 8 (KLK8) is an active serine protease in human epidermis and sweat and is
882 involved in a skin barrier proteolytic cascade. *J Biol Chem* 286:687–706.
- 883 62. Huber M, Siegenthaler G, Mirancea N, Marenholz I, Nizetic D, Breitzkreutz D,
884 Mischke D, Hohl D. 2005. Isolation and characterization of human repetin, a
885 member of the fused gene family of the epidermal differentiation complex. *J Invest*
886 *Dermatol* 124:998–1007.
- 887 63. Liffers S-T, Maghnouj A, Munding JB, Jackstadt R, Herbrand U, Schulenburg T,
888 Marcus K, Klein-Scory S, Schmiegel W, Schwarte-Waldhoff I, Meyer HE, Stühler
889 K, Hahn SA. 2011. Keratin 23, a novel DPC4/Smad4 target gene which binds 14-
890 3-3 ϵ . *BMC Cancer* 11:137.
- 891 64. Mee JB, Cork MJ, Di Giovine FS, Duff GW, Groves RW. 2006. Interleukin-1: A
892 key inflammatory mediator in psoriasis? *Cytokine* 33:72–78.
- 893 65. Ahmed ST, Darnell JE. 2009. Serpin B3/B4, activated by STAT3, promote survival
894 of squamous carcinoma cells. *Biochem Biophys Res Commun* 378:821–5.

- 895 66. Iversen OJ, Lysvand H, Slupphaug G. 2017. Pso p27, a SERPINB3/B4-derived
896 protein, is most likely a common autoantigen in chronic inflammatory diseases.
897 Clin Immunol 174:10–17.
- 898 67. Duk JM, de Bruijn HW, Groenier KH, Hollema H, ten Hoor KA, Krans M, Aalders
899 JG. 1990. Cancer of the uterine cervix: sensitivity and specificity of serum
900 squamous cell carcinoma antigen determinations. Gynecol Oncol 39:186–194.
- 901 68. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, Kobayashi
902 S, Hayashi H, Ochiai T. 2003. Prediction of survival with squamous cell carcinoma
903 antigen in patients with resectable esophageal squamous cell carcinoma. Surgery
904 133:486–94.
- 905 69. Takeshima N, Hirai Y, Katase K, Yano K, Yamauchi K, Hasumi K. 1998. The
906 value of squamous cell carcinoma antigen as a predictor of nodal metastasis in
907 cervical cancer. Gynecol Oncol 68:263–6.
- 908 70. Catanzaro JM, Sheshadri N, Pan JA, Sun Y, Shi C, Li J, Powers RS, Crawford
909 HC, Zong WX. 2014. Oncogenic Ras induces inflammatory cytokine production by
910 upregulating the squamous cell carcinoma antigens SerpinB3/B4. Nat Commun 5.
- 911 71. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J,
912 Mysliwiec M, Schmitt M, Diamandis EP. 2003. Human kallikrein 8, a novel
913 biomarker for ovarian carcinoma. Cancer Res 63:2771–2774.
- 914 72. Borgoño CA, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M,
915 Diamandis EP. 2006. Human kallikrein 8 protein is a favorable prognostic marker
916 in ovarian cancer. Clin Cancer Res 12:1487–1493.

- 917 73. Pettus JR, Johnson JJ, Shi Z, Davis JW, Koblinski J, Ghosh S, Liu Y, Ravosa MJ,
918 Frazier S, Stack MS. 2009. Multiple kallikrein (KLK 5, 7, 8, and 10) expression in
919 squamous cell carcinoma of the oral cavity. *Histol Histopathol* 24:197–207.
- 920 74. Cane' S, Bignotti E, Bellone S, Palmieri M, De Las Casas L, Roman JJ, Pecorelli
921 S, Cannon MJ, O'Brien T, Santin AD. 2004. The novel serine protease tumor-
922 associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly
923 overexpressed in cervical cancer. *Am J Obstet Gynecol* 190:60–66.
- 924 75. Ryu K-Y, Maehr R, Gilchrist CA, Long MA, Bouley DM, Mueller B, Ploegh HL,
925 Kopito RR. 2007. The mouse polyubiquitin gene UbC is essential for fetal liver
926 development, cell-cycle progression and stress tolerance. *EMBO J* 26:2693–2706.
- 927 76. Isaacson Wechsler E, Wang Q, Roberts I, Pagliarulo E, Jackson D, Untersperger
928 C, Coleman N, Griffin H, Doorbar J. 2012. Reconstruction of human
929 papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7
930 deregulation and the loss of contact inhibition in neoplastic progression. *J Virol*
931 86:6358–6364.
- 932 77. Kalinin A, Marekov LN, Steinert PM. 2001. Assembly of the epidermal cornified
933 cell envelope. *J Cell Sci* 114:3069–3070.
- 934 78. Brown DR, Bryan JT. Abnormalities of cornified cell envelopes isolated from
935 human papillomavirus type 11-infected genital epithelium.
- 936 79. Lundstrom A, Egelrud T. 1991. Stratum corneum chymotryptic enzyme: A
937 proteinase which may be generally present in the stratum corneum and with a
938 possible involvement in desquamation. *Acta Derm Venereol* 71:471–474.

- 939 80. Egelrud T, Lundström A. 1991. A chymotrypsin-like proteinase that may be
940 involved in desquamation in plantar stratum corneum. *Arch Dermatol Res*
941 283:108–112.
- 942 81. Egelrud T, Hofer PA, Lundström A. 1988. Proteolytic degradation of desmosomes
943 in plantar stratum corneum leads to cell dissociation in vitro. *Acta Derm Venereol*
944 68:93–7.
- 945 82. Yamasaki K. 2006. Kallikrein-mediated proteolysis regulates the antimicrobial
946 effects of cathelicidins in skin. *FASEB J* 20:2068–2080.
- 947 83. Petty RD, Kerr KM, Murray GI, Nicolson MC, Rooney PH, Bissett D, Collie-Duguid
948 ESR. 2006. Tumor transcriptome reveals the predictive and prognostic impact of
949 lysosomal protease inhibitors in non-small-cell lung cancer. *J Clin Oncol* 24:1729–
950 1744.
- 951 84. Catanzaro JM, Guerriero JL, Liu J, Ullman E, Sheshadri N, Chen JJ, Zong WX.
952 2011. Elevated expression of squamous cell carcinoma antigen (SCCA) is
953 associated with human breast carcinoma. *PLoS One* 6.
- 954 85. Pontisso P, Calabrese F, Benvegnù L, Lise M, Belluco C, Ruvoletto MG, Marino
955 M, Valente M, Nitti D, Gatta A, Fassina G, Fassina G. 2004. Overexpression of
956 squamous cell carcinoma antigen variants in hepatocellular carcinoma. *Br J*
957 *Cancer* 90:833–7.
- 958 86. de Koning PJA, Kummer JA, de Poot SAH, Quadir R, Broekhuizen R, McGettrick
959 AF, Higgins WJ, Devreese B, Worrall DM, Bovenschen N. 2011. Intracellular
960 serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death.

- 961 PLoS One 6:e22645.
- 962 87. Sun Y, Sheshadri N, Zong WX. 2016. SERPINB3 and B4: From biochemistry to
963 biology. *Semin Cell Dev Biol*.
- 964 88. Mitsuishi K, Nakamura T, Sakata Y, Yuyama N, Arima K, Sugita Y, Suto H,
965 Izuhara K, Ogawa H. 2005. The squamous cell carcinoma antigens as relevant
966 biomarkers of atopic dermatitis. *Clin Exp Allergy* 35:1327–1333.
- 967 89. Takeda A, Higuchi D, Takahashi T, Ogo M, Baciú P, Goetinck PF, Hibino T. 2002.
968 Overexpression of serpin squamous cell carcinoma antigens in psoriatic skin. *J*
969 *Invest Dermatol* 118:147–154.
- 970 90. Kuwae K, Matsumoto-Miyai K, Yoshida S, Sadayama T, Yoshikawa K, Hosokawa
971 K, Shiosaka S. 2002. Epidermal expression of serine protease, neuropsin (KLK8)
972 in normal and pathological skin samples. *J Clin Pathol Mol Pathol* 55:235–241.
- 973 91. McLaughlin-Drubin ME, Wilson S, Mullikin B, Suzich J, Meyers C. 2003. Human
974 papillomavirus type 45 propagation, infection, and neutralization. *Virology* 312:1–7.
- 975 92. Meyers C, Mayer TJ, Ozburn MA. 1997. Synthesis of infectious human
976 papillomavirus type 18 in differentiating epithelium transfected with viral DNA. *J*
977 *Virol* 71:7381–7386.
- 978 93. McLaughlin-Drubin ME, Meyers C. 2005. Propagation of infectious, high-risk HPV
979 in organotypic “raft” culture, p. 171–186. *In* Human Papillomaviruses. Humana
980 Press, New Jersey.
- 981 94. Meyers C. 1996. Organotypic (raft) epithelial tissue culture system for the

- 982 differentiation-dependent replication of papillomavirus. *Methods Cell Sci* 18:201–
983 210.
- 984 95. Ozbun MA, Meyers C. 1997. Characterization of late gene transcripts expressed
985 during vegetative replication of human papillomavirus type 31b. *J Virol* 71:5161–
986 72.
- 987 96. Conway MJ, Alam S, Ryndock EJ, Cruz L, Christensen ND, Roden RBS, Meyers
988 C. 2009. Tissue-spanning redox gradient-dependent assembly of native human
989 papillomavirus type 16 virions. *J Virol* 83:10515–10526.
- 990 97. Biryukov J, Cruz L, Ryndock EJ, Meyers C. 2015. Native human papillomavirus
991 production, quantification, and infectivity analysis, p. 317–331. *In* . Humana Press,
992 New York, NY.
- 993 98. Meyers C, Alam S, Mane M, Hermonat PL. 2001. Altered biology of adeno-
994 associated virus type 2 and human papillomavirus during dual infection of natural
995 host tissue. *Virology* 287:30–39.
- 996 99. Peterson GL. 1977. A simplification of the protein assay method of Lowry et al.
997 which is more generally applicable. *Anal Biochem* 83:346–356.
- 998 100. Calabrese F, Lunardi F, Balestro E, Marulli G, Perissinotto E, Loy M, Nannini N,
999 Valente M, Saetta M, Agostini C, Rea F. 2012. Serpin B4 isoform overexpression
1000 is associated with aberrant epithelial proliferation and lung cancer in idiopathic
1001 pulmonary fibrosis. *Pathology* 44:192–198.
- 1002 101. Shinoda Y, Kozaki K, Imoto I, Obara W, Tsuda H, Mizutani Y, Shuin T, Fujioka T,

- 1003 Miki T, Inazawa J. 2007. Association of KLK5 overexpression with invasiveness of
1004 urinary bladder carcinoma cells. *Cancer Sci* 98:1078–1086.
- 1005 102. Yousef GM, Polymeris ME, Yacoub GM, Scorilas A, Soosaipillai A, Popalis C,
1006 Fracchioli S, Katsaros D, Diamandis EP. 2003. Parallel overexpression of seven
1007 kallikrein genes in ovarian cancer. *Cancer Res* 63:2223–2227.
- 1008 103. Planque C, de Monte M, Guyetant S, Rollin J, Desmazes C, Panel V, Lemarié E,
1009 Courty Y. 2005. KLK5 and KLK7, two members of the human tissue kallikrein
1010 family, are differentially expressed in lung cancer. *Biochem Biophys Res Commun*
1011 329:1260–1266.
- 1012 104. Yousef GM, Scorilas A, Kyriakopoulou LG, Rendl L, Diamandis M, Ponzzone R,
1013 Biglia N, Giai M, Roagna R, Sismondi P, Diamandis EP. 2002. Human kallikrein
1014 gene 5 (KLK5) expression by quantitative PCR: An independent indicator of poor
1015 prognosis in breast cancer. *Clin Chem* 48:1241–1250.
- 1016 105. Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Inoue H, Nagahara H, Murayama
1017 S, Mori M. 2005. Clinical significance of human kallikrein gene 6 messenger RNA
1018 expression in colorectal cancer. *Clin Cancer Res* 11:2889–93.
- 1019 106. Marimuthu A, Chavan S, Sathe G, Sahasrabuddhe NA, Srikanth SM, Renuse S,
1020 Ahmad S, Radhakrishnan A, Barbhuiya MA, Kumar R V., Harsha HC, Sidransky
1021 D, Califano J, Pandey A, Chatterjee A. 2013. Identification of head and neck
1022 squamous cell carcinoma biomarker candidates through proteomic analysis of
1023 cancer cell secretome. *Biochim Biophys Acta - Proteins Proteomics* 1834:2308–
1024 2316.

- 1025 107. Yousef GM, Borgoño CA, Popalis C, Yacoub GM, Polymeris M-E, Soosaipillai A,
1026 Diamandis EP. 2004. In-silico analysis of kallikrein gene expression in pancreatic
1027 and colon cancers. *Anticancer Res* 24:43–51.
- 1028 108. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, Diamandis EP. 2008. Human
1029 kallikrein 8 expression in salivary gland tumors. *Head Neck Pathol* 2:169–174.
- 1030 109. Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, Diamandis EP,
1031 Goodglick L. 2008. A multiparametric serum kallikrein panel for diagnosis of non-
1032 small cell lung carcinoma. *Clin Cancer Res* 14:1355–62.
- 1033 110. White NMA, Mathews M, Yousef GM, Prizada A, Fontaine D, Ghatage P,
1034 Popadiuk C, Dawson L, Doré JJE. 2009. Human kallikrein related peptidases 6
1035 and 13 in combination with CA125 is a more sensitive test for ovarian cancer than
1036 CA125 alone. *Cancer Biomarkers* 5:279–287.
- 1037 111. Wu Z-S, Wu Q, Yang J-H, Wang H-Q, Ding X-D, Yang F, Xu X-C. 2008.
1038 Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in
1039 breast cancer. *Int J Cancer* 122:2050–2056.
- 1040 112. Riedel F, Götte K, Schwalb J, Hörmann K. 2000. Serum levels of matrix
1041 metalloproteinase-2 and -9 in patients with head and neck squamous cell
1042 carcinoma. *Anticancer Res* 20:3045–9.
- 1043 113. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S,
1044 Mazzarino MC. 2005. Matrix metalloproteinases as diagnostic (MMP-13) and
1045 prognostic (MMP-2, MMP-9) markers of prostate cancer. *Urol Res* 33:44–50.

- 1046 114. Yen C-Y, Chen C-H, Chang C-H, Tseng H-F, Liu S-Y, Chuang L-Y, Wen C-H,
1047 Chang H-W. 2009. Matrix metalloproteinases (MMP) 1 and MMP10 but not
1048 MMP12 are potential oral cancer markers. *Biomarkers* 14:244–249.
- 1049 115. Deraz EM, Kudo Y, Yoshida M, Obayashi M, Tsunematsu T, Tani H, Siriwardena
1050 SBSM, Kiekhaee MR, Qi G, Iizuka S, Ogawa I, Campisi G, Muzio L Lo, Abiko Y,
1051 Kikuchi A, Takata T. 2011. MMP-10/stromelysin-2 promotes invasion of head and
1052 neck cancer. *PLoS One* 6:e25438.
- 1053 116. Mathew R, Khanna R, Kumar R, Mathur M, Shukla NK, Ralhan R. 2002.
1054 Stromelysin-2 overexpression in human esophageal squamous cell carcinoma:
1055 potential clinical implications. *Cancer Detect Prev* 26:222–228.
- 1056 117. Rochefort H, Cavailles V, Augereau P, Capony F, Maudelonde T, Touitou I,
1057 Garcia M. 1989. Overexpression and hormonal regulation of pro-cathepsin D in
1058 mammary and endometrial cancer. *J Steroid Biochem* 34:177–182.
- 1059 118. Athanassiadou P, Sakellariou V, Petrakakou E, Athanassiades P, Zerva C, Liossi
1060 A, Michalas S. 1998. Cathepsin D immunoreactivity in ovarian cancer: Correlation
1061 with prognostic factors. *Pathol Oncol Res* 4:103–107.
- 1062 119. Santamaría I, Velasco G, Cazorla M, Fueyo A, Campo E, López-Otín C. 1998.
1063 Cathepsin L2, a novel human cysteine proteinase produced by breast and
1064 colorectal carcinomas. *Cancer Res* 58:1624–30.
- 1065
- 1066

1067

1068 Table 1. Viral titers of organotypic rafts

Raft Identification	Viral particles per raft
16HCK-1, replicate 1	9.38×10^7
16HCK-1, replicate 2	1.18×10^7
16HCK-2, replicate 1	5.25×10^8
16HCK-2, replicate 2	6.5×10^9
16HCK-3, replicate 1	5.81×10^7
16HCK-3, replicate 2	1.6×10^9

1069

1070

1071 Table 2. Top 50 upregulated genes with productive HPV16 infection

GENE	FUNCTION	FOLD CHANGE
<i>MT1G</i>	Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids.	12.032

<i>MT1H</i>	Mineral absorption/ metabolism	7.679
<i>TGFBR3</i>	Binds to TGF-beta. Could be involved in capturing and retaining TGF-beta for presentation to the signaling receptors	7.295
<i>KLHL35</i>	Kelch-like family member. Kelch-repeat β -propellers are generally involved in protein-protein interactions	5.814
<i>DLK2</i>	Calcium ion binding and protein dimerization activity	5.057
<i>FBLN1</i>	Cell adhesion/ migration/ ECM architecture organization	5.056
<i>ASS1</i>	Arginine biosynthetic pathway	4.446
<i>GPER</i>	G Protein coupled estrogen receptor; cAMP signaling, calcium mobilization	4.446
<i>TDRD9</i>	Probable ATP binding RNA helicase	4.393
<i>TWIST1</i>	Transcription factor, role in cell lineage determination and differentiation	4.208
<i>FANCE</i>	Member of the Fanconi anemia complementation group E	4.183
<i>JAM3</i>	Cell to cell adhesion in epithelial and endothelial cells	4.169
<i>CDKN2A</i>	Cell cycle regulation	4.122
<i>TSPAN4</i>	Cell surface protein that mediate cell development,	3.733

	activation, growth and motility	
<i>LTBP4</i>	Involved in assembly, targeting and activation of TGFB1	3.718
<i>ERAP2</i>	Aminopeptidase involved in peptide trimming, MHC class I presentation	3.551
<i>LOC341230</i>	Similar to argininosuccinate synthetase	3.454
<i>MXRA5</i>	Matrix remodeling associated proteins	3.281
<i>RPS23</i>	Component of the 40S ribosomal subunit	3.23
<i>C14orf132</i>	Putative uncharacterized protein	3.165
<i>CRIP2</i>	Putative transcription factor with two LIM zinc binding domains	3.148
<i>ANGPTL2</i>	Member of the vascular endothelial growth factor family	3.061
<i>GOLPH4</i>	Involved in endosome to Golgi protein trafficking	3.058
<i>DPYSL2</i>	Cytoskeletal remodeling, endocytosis	3.013
<i>CDC7</i>	Checkpoint control kinase critical for G1/S transition	2.981
<i>FAM134B</i>	ER anchored autophagy receptor	2.947
<i>NASP</i>	Histone binding protein with a role in cell division, cell cycle progression and proliferation	2.885
<i>HEG1</i>	Calcium ion binding receptor component, may act	2.866

	through stabilization of endothelial cell junctions	
<i>ZCWPW1</i>	Zinc finger domain containing protein	2.8
<i>MTE</i>	Metallothioneins have a high content of cysteine residues that bind various heavy metals.	2.786
<i>MDC1</i>	Required for checkpoint mediated cell cycle arrest in response to DNA damage	2.783
<i>CDH13</i>	Calcium dependent cell adhesion proteins	2.775
<i>OLFML2A</i>	Extracellular matrix binding protein	2.762
<i>LOC392871</i>	Undetermined gene ortholog	2.728
<i>CYBRD1</i>	Ferric chelate reductase	2.726
<i>RASIP1</i>	Ras interacting protein required for the formation of vascular structures	2.721
<i>LOC729137</i>	Undetermined gene ortholog	2.7
<i>GNMB</i>	Type 1 transmembrane glycoprotein	2.693
<i>MOBK2B</i>	May regulate the activity of kinases	2.672
<i>LOC388494</i>	Undetermined gene ortholog	2.645
<i>C10orf54</i>	Putative uncharacterized protein	2.644
<i>E2F2</i>	E2F family of transcription factors	2.572

<i>LFNG</i>	Transferase enzyme	2.571
<i>LOC100133866</i>	Undetermined gene ortholog	2.568
<i>NFIX</i>	DNA binding protein, capable of activating transcription and replication	2.56
<i>P4HTM</i>	Prolyl hydroxylases	2.553
<i>RELL1</i>	Receptor expressed in lymphoid tissue like 1	2.551
<i>FOXQ1</i>	FOX genes involved in gene development, cell proliferation and tissue specific gene expression	2.53
<i>TJAP1</i>	Tight junction associated protein	2.527
<i>HOXA11AS</i>	Non-coding RNA gene	2.525
<i>FN3KRP</i>	Phosphorylates psicosamines and ribulosamines	2.514

1072

1073

1074 Table 3. Top 50 downregulated genes with productive HPV16 infection

GENE	FUNCTION	FOLD CHANGE
<i>RPTN</i>	Involved in the cornified cell envelope formation. Multifunctional epidermal matrix protein. Reversibly binds calcium.	-57.487

<i>SERPINB4</i>	May act as a protease inhibitor to modulate the host immune response against tumor cells	-48.016
<i>TCN1</i>	Binds Vit B12 and protects it from the acidic environment of the stomach	-34.735
<i>CST6</i>	Active cysteine protease inhibitors. Loss of function is associated with progression of primary tumor to a metastatic phenotype	-27.758
<i>KLK8</i>	Serine proteases with diverse physiological function	-25.804
<i>CEACAM6</i>	GPI anchored glycoprotein and plays a role in cell adhesion	-24.469
<i>KLK6</i>	Serine proteases regulated by steroids	-22.088
<i>KLK13</i>	Expression regulated by steroid hormones and important marker for breast cancer	-21.464
<i>RNASE7</i>	Pancreatic ribosomal protein; broad spectrum antimicrobial activity against bacteria and fungi	-20.029
<i>PRSS3</i>	Digestive protease specialized for the degradation of trypsin inhibitors. In the ileum, may be involved in defensin processing, including DEFA5	-19.968
<i>LCE1D</i>	Precursors of the cornified layers of the stratum corneum	-17.868
<i>MMP9</i>	Zinc dependent endopeptidases and major proteases	-17.142

	involved in the degradation of the ECM	
<i>FLJ22662</i>	Weak phospholipase activity. May act as an amidase or peptidase	-14.394
<i>TMEM45B</i>	Transmembrane protein 45B	-13.469
<i>DMKN</i>	Expressed in differentiated layers of the skin. Upregulated in inflammatory disease	-13.186
<i>C6orf15</i>	Uncharacterized protein coding gene	-12.641
<i>TMEM45A</i>	Paralog of TMEM45B	-12.629
<i>PNLIPRP3</i>	Triglyceride lipase activity	-11.232
<i>KRT23</i>	intermediate filament protein	-11.074
<i>ANXA9</i>	Calcium dependent phospholipid binding protein; binds ECM proteins	-10.728
<i>LCE3C</i>	Precursors of the cornified layers of the stratum corneum	-10.044
<i>S100A7</i>	Calcium binding proteins involved in cell cycle progression and cellular differentiation	-9.88
<i>EPS8L1</i>	Substrate for the Epidermal growth factor receptor	-9.659
<i>RORA</i>	Member of NR1 family of nuclear hormone receptors	-9.136
<i>LCN2</i>	Iron trafficking protein involved in apoptosis, innate immunity and renal development	-9.134

<i>LCE1E</i>	Precursors of the cornified layers of the stratum corneum	-9.067
<i>SPNS2</i>	Sphingolipid transporter with critical function in cardiovascular, immunological and neuronal development	-8.787
<i>FAM3D</i>	Related to cytokine activity	-8.734
<i>KLK7</i>	Member of the kallikrein family of serine proteases	-8.61
<i>HMOX1</i>	Heme oxygenase, an essential enzyme in heme catabolism	-8.548
<i>RNF39</i>	Role in early phase of synaptic plasticity	-8.5
<i>SH3BGRL2</i>	Protein disulphide oxidoreductase activity	-8.478
<i>C1orf68</i>	Uncharacterized protein coding gene	-8.417
<i>POF1B</i>	Key role in organization of the epithelial monolayers by regulating the actin cytoskeleton	-8.233
<i>ATP6V1C2</i>	Subunit of the peripheral V1 complex of the vacuolar ATPase	-8.232
<i>MMP10</i>	Zinc dependent endopeptidases and major proteases involved in the degradation of the ECM	-7.953
<i>LOC730833</i>	Undetermined gene ortholog	-7.935
<i>CAPNS2</i>	Calcium regulated thiol protease, role in tissue remodeling and signal transduction	-7.64

<i>KLK10</i>	Member of the kallikrein family of serine proteases	-7.553
<i>IL1RN</i>	Inhibits the activity of Interleukin-1	-7.499
<i>ABCG1</i>	Intracellular lipid transport	-7.408
<i>THEM5</i>	Role in mitochondrial fatty acid metabolism	-7.287
<i>CYP2J2</i>	Role in arachidonic acid metabolism	-7.259
<i>PRSS2</i>	Serine protease involved in defensin processing	-7.239
<i>LOC645869</i>	Undetermined gene ortholog	-6.803
<i>PSG4</i>	May play a role in regulation of innate immune system	-6.559
<i>FAM63A</i>	Role in protein turnover, deubiquitinase activity	-6.52
<i>MAP2</i>	Stabilizing/stiffening of microtubules	-6.474
<i>SLC5A1</i>	Na ⁺ /glucose cotransporter	-6.468
<i>IL1F7</i>	Interleukin 1 related gene	-6.392
<i>EPB41L3</i>	Tumor suppressor that inhibits cell proliferation and promotes apoptosis	-6.356

1075

1076

1077 Table 4. Differential gene expression between productive HPV16 infection and cancers.

Gene	Expression fold-	Cancers in which gene expression
-------------	-------------------------	---

	change in productive HPV infection	increases and/or promotes disease progression
<i>SERPINB4</i>	-48.0	HNSCC (65), cervical (67, 69), esophageal (68), lung (100), liver (85), breast (84)
<i>KLK5</i>	-3.2	Bladder (101), ovarian (102), lung (103), breast (104), oral squamous cell carcinoma (OSCC) (73)
<i>KLK6</i>	-22.1	Bladder (101), ovarian (102), colorectal (105), head and neck squamous cell carcinoma (HNSCC) (106), pancreatic (107)
<i>KLK8</i>	-25.8	Bladder (101), ovarian (102), salivary gland (108), cervical (74), OSCC (73), colorectal (107)
<i>KLK10</i>	-7.6	Ovarian (102), OSCC (73), pancreatic (107), colorectal (107)
<i>KLK13</i>	-21.5	Lung (109), ovarian (110)
<i>MMP9</i>	-17.1	Cervical (38), breast (111), HNSCC (112), prostate (113)
<i>MMP10</i>	-8.0	OSCC (114), HNSCC (115), esophageal

		(116)
<i>LCN2</i>	-9.1	Breast (40, 41), esophageal (42), pancreatic (43), ovarian (44), colorectal (45), thyroid (46)
<i>CTSD</i>	-1.5	Breast (117), ovarian (118)
<i>CTSV</i>	-2.8	Breast (119), colorectal (119)

1078

1079

1080

1081 **Figure Legends**

1082 **FIG 1. Heat map of significantly modified genes.** Raft experiments were set up with
1083 three primary HCK and 16HCK cell lines in duplicates, and the tissue were harvested at
1084 10 days of culture for RNA extraction and microarray analysis. The heat map shows
1085 genes that were significantly modulated ($p < 0.05$) at least 5-fold with HPV16 infection.

1086 **FIG 2. Enriched GO terms with lowest p-values.** GOrilla was used to perform initial
1087 GO analysis of our microarray data, and REVIGO was used to summarize the enriched
1088 GO genesets from the upregulated (A) and downregulated (B) list of genes. The entire
1089 list of GO terms can be found in Table S2 and Table S3. Met. proc.: metabolic process.

1090 **FIG 3. Protein association networks.** Online tool STRING was used to create protein
1091 functional association networks of upregulated (A-B) and downregulated (C-E) genes
1092 with >1.5 -fold modulation ($p < 0.05$). (A) Genes from GO categories related to cell cycle

1093 regulation were combined to create the network. (B) Genes from GO categories related
1094 to DNA metabolism were combined to create the network. (C) Genes from GO
1095 categories related to skin development and differentiation were combined to create the
1096 network. (D) Genes from GO categories related to inflammation and immune response
1097 were combined to create the network. (E) Genes from GO categories related to
1098 apoptosis and cell death were combined to create the network. Thicker and darker lines
1099 represent greater confidence in protein interaction based on supporting data. Genes
1100 that had no connection to any other gene within the network were excluded from the
1101 diagram.

1102 **FIG 4. RT-PCR of genes of interest.** Raft experiments were set up with three 16HCK
1103 cell lines in duplicates and six primary HCK cell lines. The raft tissues were harvested
1104 at 20 days of culture. RNA was extracted from the tissues and RT-PCR was performed
1105 to measure transcription levels of SERPINB4, KLK8, RPTN, CDK2, and UBC.
1106 Transcription levels of TATA-binding protein (TBP) was used as control to normalize
1107 each measurement (statistical significance $p < 0.05$).

1108 **FIG 5. Western blot analysis of raft tissue.** (A) Protein expression of SERPINB4,
1109 KLK8, RPTN, and KRT23 were tested with Western blots in primary HCK and 16HCK
1110 raft tissue harvested at 20 days of culture. Densitometry analysis was conducted on the
1111 Western blots (statistical significance $p < 0.05$). (B) Protein expression of Ubiquitin was
1112 tested with Western blot in primary HCK and 16HCK raft tissue harvested at 20 days of
1113 culture. Experiments were conducted in three 16HCK cell lines in duplicates and six
1114 primary HCK cell lines. GAPDH was used as control. Images were acquired with Bio-
1115 Rad ChemiDoc MP Imaging System and Image Lab Version 6.0.0 software.

1116 **FIG 6. Immunofluorescence staining of raft tissue.** The spatial protein expression
1117 of SERPINB4, RPTN, KRT23, and Ubiquitin was observed by performing
1118 immunofluorescence staining of primary HCK and 16HCK raft tissue fixed at 20 days of
1119 culture (green: target protein, blue: nuclear staining). Experiments were conducted in
1120 three 16HCK cell lines in duplicates and six primary HCK cell lines. Magnification 200x.
1121 H&E: hematoxylin and eosin staining. Images were acquired with Nikon Eclipse 80i
1122 microscope and NIS Elements version 4.4 software.

1123

1124 **Supplemental Material**

1125 Table S1. Genes significantly modulated with HPV16 infection in human cervical tissue.

1126 Table S2. GO analysis of genes upregulated with HPV16 infection in human cervical
1127 epithelium. GO analysis performed with GOrilla and summarized with REVIGO.

1128 Table S3. GO analysis of genes downregulated with HPV16 infection in human cervical
1129 epithelium. GO analysis performed with GOrilla and summarized with REVIGO.

1130 Table S4. Upregulated genes: GO terms related to cell cycle.

1131 Table S5. Upregulated genes: GO terms related to DNA metabolism.

1132 Table S6. Downregulated genes: GO terms related to skin development.

1133 Table S7. Downregulated genes: GO terms related to inflammation.

1134 Table S8. Downregulated genes: GO terms related to cell death.




FIG 1. Heat map of significantly modified genes. Raft experiments were set up with three primary HCK and 16HCK cell lines in duplicates, and the tissue were harvested at 10 days of culture for RNA extraction and microarray analysis. The heat map shows genes that were significantly modulated ($p < 0.05$) at least 5-fold with HPV16 infection.




FIG 2. Enriched GO terms with lowest p-values. GOrilla was used to perform initial GO analysis of our microarray data, and REVIGO was used to summarize the enriched GO genesets from the upregulated (A) and downregulated (B) list of genes. The entire list of GO terms can be found in Supplementary Table 2 and Supplementary Table 3. Met. proc.: metabolic process.




FIG 3. Protein association networks. Online tool STRING was used to create protein functional association networks of upregulated (A-B) and downregulated (C-E) genes with >1.5-fold modulation ($p < 0.05$). (A) Genes from GO categories related to cell cycle regulation were combined to create the network. (B) Genes from GO categories related to DNA metabolism were combined to create the network. (C) Genes from GO categories related to skin development and differentiation were combined to create the network. (D) Genes from GO categories related to inflammation and immune response were combined to create the network. (E) Genes from GO categories related to apoptosis and cell death were combined to create the network. Thicker and darker lines represent greater confidence in protein interaction based on supporting data. Genes that had no connection to any other gene within the network were excluded from the diagram.




FIG 4. RT-PCR of genes of interest. Raft experiments were set up with three 16HCK cell lines in duplicates and six primary HCK cell lines. The raft tissues were harvested at 20 days of culture. RNA was extracted from the tissues and RT-PCR was performed to measure transcription levels of SERPINB4, KLK8, RPTN, CDK2, and UBC. Transcription levels of TATA-binding protein (TBP) was used as control to normalize each measurement (statistical significance $p < 0.05$).




FIG 5. Western blot analysis of raft tissue. (A) Protein expression of SERPINB4, KLK8, RPTN, and KRT23 were tested with Western blots in primary HCK and 16HCK raft tissue harvested at 20 days of culture. Densitometry analysis was conducted on the Western blots (statistical significance $p < 0.05$). (B) Protein expression of Ubiquitin was tested with Western blot in primary HCK and 16HCK raft tissue harvested at 20 days of culture. Experiments were conducted in three 16HCK cell lines in duplicates and six primary HCK cell lines. GAPDH was used as control. Images were acquired with Bio-Rad ChemiDoc MP Imaging System and Image Lab Version 6.0.0 software.




FIG 6. Immunofluorescence staining of raft tissue. The spatial protein expression of SERPINB4, RPTN, KRT23, and Ubiquitin was observed by performing immunofluorescence staining of primary HCK and 16HCK raft tissue fixed at 20 days of culture (green: target protein, blue: nuclear staining). Experiments were conducted in three 16HCK cell lines in duplicates and six primary HCK cell lines. Magnification 200 \times . H&E: hematoxylin and eosin staining. Images were acquired with Nikon Eclipse 80i microscope and NIS Elements version 4.4 software.